BMY Gains 11.4% in a Month: Should You Buy, Sell or Hold the Stock?

Key Takeaways BMY shares rose 11.4% in a month as growth brands offset legacy generic erosion.Opdivo, Reblozyl, Breyanzi and Camzyos powered 55% of 2025 revenues.BMY eyes six key pipeline readouts and targets $2B in annual cost savings by 2027.Shares of Bristol Myers Squibb (BMY) have gained 11.4% in the past month, outperforming the industry’s growth of 5%. The stock has also outperformed the sector and the S&P 500 in the same time frame.The going has been good for BMY in recent months. Robust fourth-quart ...